BESPOKE CRC: ctDNA for Informing Adjuvant Chemotherapy in Colorectal Cancer

Pashtoon Kasi, MD, MS, Weill Cornell Medicine, breaks down the BESPOKE CRC study, a multicenter, prospective, observational evaluation of the ability of a tumor-informed ctDNA assay to inform adjuvant chemotherapy treatment decisions in stage 2/3 colorectal cancer.

Dr. Kasi explains what the results suggest about ctDNA-based MRD detection and benefit from adjuvant chemotherapy, as well as how the data presented at the ASCO GI Symposium on the expansion cohort adds to our understanding in this setting.

View Dr. Kasi’s continued comments on the NEST-1 trial for pMMR/MSS colorectal cancer.

All images and data were presented at the 2024 American Society of Clinical Oncology® Gastrointestinal Cancer Symposium.